Vonafexor
Phase 2Small molecule
Vonafexor is one of 32 small molecule programs targeting Hepatitis. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
39 competitors in Hepatitis
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Byetta
AstraZenecaApproved
Viread
GileadApproved
Tyzeka
NovartisApproved
Sovaldi
GileadApproved
Glucophage
EMD SeronoApproved
Singulair
OOrganon and Co
Approved
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatitis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vonafexor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEnyo Pharma